Journal
ANTIVIRAL RESEARCH
Volume 77, Issue 1, Pages 6-13Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2007.08.010
Keywords
WNV; passive immunization; recombinant antibody; gene delivery; adenovirus
Categories
Funding
- NIAID NIH HHS [R03 AI053084, U54 AI057157-05, 5U54 AI057157, R01 AI049258-05, 1R03 AI53084, 1R01 AI049258, R21 AI054538, U54 AI057157, R03 AI053084-03, 5R21 AI054538, R21 AI054538-01, R01 AI049258] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054538, U54AI057157, R01AI049258, R03AI053084] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Gene-based delivery of recombinant antibody genes is a promising therapeutic strategy offering numerous advantages including sustained antibody levels, better safety profile and lower production cost. Here we describe generation of a recombinant antibody Fc-9E2 comprising a fusion protein between human Fc of IgGI and a single-chain Fv derived from a hybridoma 9E2 secreting a mAb neutralizing West Nile virus (WNV). Fc-9E2 was shown to retain parental mAb's specificity and WNV-neutralizing capacity. Adenovirus-mediated in vivo delivery of the antibody gene resulted in sustained Fc-9E2 serum levels leading to abrogation of lethal WNV infection in an animal model. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
